ArticleThe Canadian veterinary journal = La revue veterinaire canadienne2025
Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats.
Article in The Canadian veterinary journal = La revue veterinaire canadienne, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats.Veterinary dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our objective was to provide preliminary clinical and laboratory data and the minimum effective dose for long-term (≥ 7 mo) treatment of feline allergic pruritus with oclacitinib. We studied 14 privately owned cats with pruritic allergic dermatitis controlled with oclacitinib treatment. Clinical data and results of blood testing (at the onset and at least once thereafter) during treatment were retrospectively evaluated. The median initial dosage of oclacitinib was 1.1 mg/kg q12h. In 7 animals, the maintenance dose could be reduced by ≥ 50%, usually after 15 d of treatment. The median duration of treatment was 15.5 mo. An FeLV-FIV test was conducted in 10 cats and all were negative. During treatment, 4 cats had non-dermatologic disorders that resolved without changing the oclacitinib dosing schedule. Alterations in blood tests during treatment were mild and frequently transient and included hypercholesterolemia, increased alanine aminotransferase and/or creatinine, and hyperglycemia. Limited and transitory disruptions in platelets and white cell lineage numbers were identified in some cats but none required specific treatment or discontinuation of oclacitinib. Alterations observed in the 14 cats treated with oclacitinib for a median of 15.5 mo were few and mild. No direct relationships were apparent between laboratory abnormalities or clinical signs and the dosing schedule of oclacitinib. A reduction of the daily dose to control allergic pruritus was feasible in 7/14 cats. Key clinical message: Based on the 14 cases included, long-term treatment with oclacitinib appeared to be well-tolerated and effective for managing feline allergic pruritus. However, close monitoring is recommended, and prospective studies with larger samples are needed to confirm these results.
Indexed as
Identifiers
40786738PMC12330796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.